ArticleKidney international2019
The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward.
Article in Kidney international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Safety and Efficacy of Spironolactone in Dialysis-Dependent Patients: Meta-Analysis of Randomized Controlled Trials.Frontiers in medicine · 2022Pooled it
- Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney international · 2020Guideline
- Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Trial
- Mineralocorticoid Receptor Antagonists in Dialysis.American journal of nephrology · 2026Review
- Management of Chronic Heart Failure in Dialysis Patients: A Challenging but Rewarding Path.Reviews in cardiovascular medicine · 2024Review
- Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA).Clinical kidney journal · 2023Article
- Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality-A Comprehensive Review.Journal of cardiovascular development and disease · 2023Review
- Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients.Drug design, development and therapy · 2023Review
- Overview of research progress on the association of dietary potassium intake with serum potassium and survival in hemodialysis patients, does dietary potassium restriction really benefit hemodialysis patients?Frontiers in endocrinology · 2023Review
- Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future.Journal of human hypertension · 2022Review
- Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.Nature reviews. Nephrology · 2022Review
- Inflammation: a putative link between phosphate metabolism and cardiovascular disease.Clinical science (London, England : 1979) · 2021Review
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.European heart journal · 2021Review
- The expanding class of mineralocorticoid receptor modulators: New ligands for kidney, cardiac, vascular, systemic and behavioral selective actions.Acta endocrinologica (Bucharest, Romania : 2005)Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Spin-D (Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent End-Stage Renal Disease) and MiREnDa (Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease) trials taken together provide the reassuring demonstration that up to 25 mg/d spironolactone is reasonably safe, provided maintenance hemodialysis patients are properly monitored and investigators use a per-protocol therapeutic algorithm to manage hyperkalemia. These results should encourage and reassure the investigators of the 2 currently ongoing, large, international, major-outcome clinical trials, both of which are using spironolactone up to 25 mg/d: ACHIEVE (Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease trial; NCT03020303) and ALCHEMIST (ALdosterone antagonist Chronic HEModialysis Interventional Survival Trial; NCT01848639).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.